Abstract
Ever since its establishment in 1995, the European Medicines Agency (EMA) has been committed to transparency. That said, as of late the Agency has been criticized for lacking it. To address this criticism, the Agency is attempting to become even more transparent. In this commentary the author argues that the EMA is now moving almost too quickly toward complete transparency. Before launching a number of new transparency initiatives, it should consider arranging some workshops on the topic as well as pretesting its communication messages before they are put in the public domain.